Powered by: Motilal Oswal
17/08/2022 12:55:09 PM | Source: ICICI Direct
Hold Abbott India Ltd For Target Rs.21140 - ICICI Direct
News By Tags | #2222 #872 #3961 #642 #1302
Hold Abbott India Ltd For Target Rs.21140 - ICICI Direct

Weak poultry performance continues to weigh on numbers

About the stock: Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women’s health, GI, metabolic, pain, CNS among othe

* The company’s top five brands - (Mixtard, Thyronorm, Novomix, Udiliv and Duphaston) together posted revenue CAGR of ~6.6% MAT, March 2019-22

* Abbott has 140+ brands in segments of women’s health, gastroenterology, metabolics, CNS, multi-specialty, vaccines & consumer healthQ1FY23 Results: Numbers weak as poultry farm economics turned adverse.

Q1FY23 Results: Abbott India’s revenues were in line with our expectations while margins were marginally lower

* Sales were up 7% YoY to | 1304 crore

* EBITDA was at | 270 crore, up 2% YoY with margins at 20.7%

* Consequent PAT was at | 206 crore (up 5% YoY

What should investors do? Abbott’s share price has grown by ~2.2x over the past three years (from ~| 8434 in August 2019 to ~| 18762 levels in Aug 2022)

* Downgrade from BUY to HOLD as valuations at current level largely factor power brands growth momentum and growing traction for new brands

Target Price and Valuation: Valued at | 21140 i.e. 40x FY24E EPS of | 528.6

Key triggers for future price performance:

* Consistency in brand-driven growth driven by favourable market dynamics with doctor prescription stickiness and lower perceived risk factors

* NLEM price hike of ~10.8% for estimated NLEM portfolio exposure of ~21% for Abbott may have positive impact on price led growth

* Focus on new launches, which is fairly consistent (+100 launches and line extensions in the last 10 years)

* Future launches from key divisions, along with brand extensions and access to innovative molecules from global parent to drive growth

Alternate Stock Idea: Apart from Abbott, in our healthcare coverage we like Pfizer.

* Pfizer is following a measured approach with de-focusing and hiving off of tail brands and focusing on core strengths areas such as vaccines, pain management, VMS, GI and CVS

 

To Read Complete Report & Disclaimer Click Here

 

For More ICICI Securities Disclaimer https://www.icicisecurities.com/AboutUs.aspx About=7

 

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here